History
The Saarland University Medical Center (Universitätsklinikum des Saarlandes - UKS) was founded in 1947 on the site of the former Palatine Sanatorium and Nursing Home, which was founded in 1909. Today, the entire spectrum of medicine is offered on a campus harmoniously embedded in the surrounding forest. The UKS plays a leading role in medical teaching, research and patient care in the Saarland and bordering Rhineland Palatinate provinces, as well as in the neighboring France and Luxemburg regions.
Profile
The UKS Center of Integrated Oncology and Palliative Medicine (UKS Zentrum für Integrierte Onkologie und Palliativmedizin) is incorporated within the Saarland University Medical Center and is responsible for the treatment of hematological malignancies and solid tumors. On our oncologic ward (68 beds) and palliative care ward (12 beds) as well as in our outpatient offices (8 in total) we provide optimized, academic-level interdisciplinary care through close cooperation of the following departments:
- Department of Hematology, Oncology, Rheumatology and Clinical Immunology
- Center for Cross-age Palliative Care and Pediatric Pain Management
Specialities
The Center includes consultants of various specialties including hemato-oncology, pediatrics, internal medicine, general practice and anesthesiology. Besides broad hemato-oncologic and palliative care, specialized treatment forms can be offered including psychological support, pastoral/spiritual support, animal-assisted therapy, music- and art therapy, as well as acupuncture.
Palliative and Supportive Care
Supportive and palliative care plays an important role in the management of hematological and oncological malignancies. Many patients with cancer do not require immediately any kind of direct anti-tumor treatment. Others, although it is indicated, cannot receive any or have discontinued therapy for a variety of reasons. As a primary care provider, we accompany and support each of those patients through every stage of their disease. This may mean regular administration of blood products, hematopoietic growth factors, pharmaceutical and interventional symptom management and control, psychological, social support, and close monitoring for changes in status. For each patient, an individualized treatment management plan is prepared.
Last update: August 2021
